0.37
+8.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Streamex
From its filings with the US Securities and Exchange Commission
Streamex is based in Winter Park, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker STEX. The SEC classifies its business as security & commodity brokers, dealers, exchanges & services. In the fiscal year to 31 December 2024, it reported revenue of $40,000.
Company’s principal business is tokenized finance and real-world asset (“RWA”) digitization, conducted through Streamex.
Inc. (“ViralClear”). As of December 31, 2025, the Company owned approximately 69.7% of ViralClear’s outstanding equity.
July 2, 2020, the Company formed another Delaware subsidiary, NeuroClear Technologies, Inc., which was renamed BioSig AI Sciences, Inc.
As of December 31, 2025, the Company owned approximately 84.5% of BioSig AI’s outstanding equity.
AI was established to pursue clinical needs of cardiac and neurological disorders through recordings and analyses of action potentials.
July 7, 2025, we entered into a Debenture Purchase Agreement (as amended, the “DPA”) with YA II PN, Ltd.
Regulatory developments may impact product design, market access, operating costs, and the timing or feasibility of commercial launches.
Metals. GLDY is currently being offered and sold on the Streamex Platform to accredited and qualified investors.
July 2, 2020, the Company formed NeuroClear Technologies, Inc., a Delaware corporation, which was renamed to BioSig AI Sciences, Inc.
July 2021, we received EU certificates of registration for the following trademarks: “ACCUVIZ”, “WCT+”, and “COMBIO”.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 22 Sept 2014
- Employees
- 6
- Website
- biosigtech.com ↗
- Head office
- 165 LINCOLN AVE 2ND FLOOR, WINTER PARK, FL, 32789
- Incorporated in
- DE
- Classification
- Security & Commodity Brokers, Dealers, Exchanges & Services
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Morgan LekstromChairman of the Board, since 2025
- Mr. Henry McphieChief Executive Officer, Director, since 2025
- Mr. Ferdinand GroenewaldInterim Chief Financial Officer$106,500
- Mr. Mitchell WilliamsChief Investment Officer
- Mr. Anthony AmatoDirector, since 2024$2.3m
- Mr. Steven AbelmanIndependent Director$125,550
- Mr. Chris BaerIndependent Director$125,550
- Mr. Donald BrowneIndependent Director$125,550
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 42
- Social
- 40
- Governance
- 32
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioSig Technologies develops PURE EP System for intracardiac signal processing in electrophysiology studies.
- The company focuses on atrial fibrillation and ventricular tachycardia procedures with its biomedical platform.
- Streamex Corp employs 6 full-time employees in the Health Care sector.
Weaknesses
- BioSig Technologies has 49 full-time employees, which is higher than Streamex Corp's 6 employees.
- The company's IPO was on 22 September 2014, indicating limited market history.
- Streamex Corp's small employee count of 6 may limit operational capacity.
Opportunities
- The Health Care sector offers growth opportunities for biomedical signal processing technologies.
- Electrophysiology studies and cardiac catheter ablation procedures are expanding markets.
- Streamex Corp can leverage PURE EP System for broader medical applications.
Threats
- BioSig Technologies' focus on specific cardiac procedures may limit market reach.
- The Health Care industry faces regulatory challenges for new medical technologies.
- Streamex Corp's small size could hinder competitiveness against larger firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.